British journal of clinical pharmacology最新文献

{"title":"Population pharmacokinetics and exposure-response modelling of firsekibart (GenSci048) in patients with acute gout flare: Implications for fixed-dose optimization.","authors":"Kun Wang, Juan Yang, Fengyan Xu, Lu Liu, Tianhong Luo, Qian Xu, Weiwei Gao, Guangli Ma, Yongchao Fu, Xiaoyan Zhu","doi":"10.1002/bcp.70607","DOIUrl":"https://doi.org/10.1002/bcp.70607","url":null,"abstract":"<p><strong>Background and objectives: </strong>Firsekibart (formerly GenSci048 or genakumab) is a humanized anti-IL-1β monoclonal antibody developed for acute gouty flares in patients unsuitable for standard therapies. This study characterized its population pharmacokinetics (PopPK), assessing covariate effects, and established exposure-response (E-R) relationships to guide dosing.</p><p><strong>Methods: </strong>Data from four clinical trials involving 296 subjects (2287 concentrations) were pooled to develop a PopPK model using NONMEM with stepwise covariate screening. A one-compartment model with sequential zero- and first-order absorption was utilized. E-R analyses were conducted to assess efficacy (dVAS_72h, defined as achieving ≥50% reduction in Visual Analog Scale [VAS] scores from baseline measured at 72 h) and safety (dyslipidaemia/hepatic dysfunction/infectious and invasive diseases) using logistic regression.</p><p><strong>Results: </strong>Body weight significantly affected clearance and distribution volume. Hepatic or renal impairment caused exposure differences of less than 27%. No exposure-dependent safety trends were identified across the evaluated exposure range. Although exposure-response trends were observed across the broader dose range, the gradient within the exposure range achieved by 195-200 mg was shallow, consistent with a plateau. Simulations indicated that at the 200-mg dose, more than 95% of patients attained exposures associated with at least 85% probability of achieving dVAS_72h. Firsekibart also markedly reduced flare recurrence over 12 weeks compared with the control group.</p><p><strong>Conclusion: </strong>Firsekibart demonstrated predictable pharmacokinetics, a favourable safety profile, and robust efficacy coverage at the 200-mg fixed dose. These findings support fixed-dosing for patients with acute gout flares who are intolerant of, unsuitable for, or inadequately responsive to standard-of-care therapies.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double-blind trial.","authors":"Anastasia Nikopoulou, Vasileios Grosomanidis, Aikaterina Poulopoulou, Timoleon-Achilleas Vyzantiadis, Chryssa Pourzitaki, Ioannis Patsalas, Georgia G Tsaousi","doi":"10.1002/bcp.70606","DOIUrl":"https://doi.org/10.1002/bcp.70606","url":null,"abstract":"<p><strong>Aim: </strong>Dexmedetomidine (DEX) seems to hold a potential neuroprotective role, possibly mediated by the attenuation of oxidative stress and neuroinflammation. This study aimed to delineate the effect of DEX used as an adjunct anaesthetic on cerebral oxygenation, cerebral injury and the release of inflammatory markers in brain tumour surgery.</p><p><strong>Methods: </strong>Fifty-six patients undergoing craniotomy for brain tumour excision were randomly assigned to receive either DEX (1 μg/kg for 10 min and thereafter 0.7 μg/kg/h) or placebo. Arterial and jugular-bulb blood samples were collected at predefined time-points, whereas a concomitant hemodynamic profile was obtained intraoperatively. S100B protein, neuron-specific enolase (NSE), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and cortisol levels were determined at baseline and 6 and 24 h postoperatively.</p><p><strong>Results: </strong>Demographic and perioperative characteristics were comparable between groups. Propofol consumption was considerably reduced in DEX-treated patients (p < 0.001). Measured (jugular-bulb oxygen saturation and partial pressure of oxygen) and estimated (oxygen and carbon dioxide arterial-jugular differences, brain oxygen extraction ratio) cerebral oxygenation indices were favourably affected by DEX infusion (p < 0.05), yet this effect was valid for 15 min (p < 0.05), corresponding to transient systemic hemodynamic augmentation. Moreover, postoperative S100B, NSE, TNF-α, IL-6 and cortisol levels were significantly attenuated in the DEX group (p < 0.01).</p><p><strong>Conclusion: </strong>DEX may attenuate the release of cerebral injury and neuroinflammation biomarkers and transiently improve hemodynamics and cerebral oxygenation during brain tumour surgery. Nonetheless, these surrogate effects do not establish clinically relevant neuroprotection, and potential dose-related hemodynamic instability warrants cautious, individualized use.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort.","authors":"Hong Huang, Yan Geng, Yong Fan, Juan Zhao, Zhuoli Zhang","doi":"10.1002/bcp.70598","DOIUrl":"https://doi.org/10.1002/bcp.70598","url":null,"abstract":"<p><strong>Aims: </strong>The cardiovascular risk of tofacitinib has been highly concerned. In this study, we investigated the trajectory of lipid profiles in patients with rheumatoid arthritis (RA) after receiving tofacitinib.</p><p><strong>Methods: </strong>Patients were recruited from the prospective CENTRA cohort of RA patients. The data of RA disease activity, triglyceride (TG), total cholesterol (TCHO), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and ratios of TCHO/HDL and LDL/HDL were collected at baseline, week 4, 12, 24 and 52. Lipid and lipoprotein concentrations were compared between the tofacitinib exposure group and the non-exposure group by propensity score matching (PSM).</p><p><strong>Results: </strong>Totally 374 patients were enrolled, with 137 received tofacitinib and 237 not. After 4 weeks of tofacitinib treatment, the levels of TG, TCHO, HDL and LDL were increased. TCHO and LDL concentrations returned to baseline levels by weeks 24 and 52, respectively, while TG and HDL levels remained elevated throughout 52 weeks. After 1:1 PSM, 133 patients in tofacitinib exposure group and 133 in non-exposure group were identified. Compared to the non-exposure group, the tofacitinib-exposure group showed significantly increased TCHO levels at week 4 and continuously higher TCHO levels till week 24; HDL and LDL levels were also elevated from week 12 to week 24.</p><p><strong>Conclusions: </strong>Four-week exposure to tofacitinib induced elevation of TG, TCHO, HDL and LDL in serum. LDL and TCHO returned to baseline levels at week 24 and week 52, respectively; nevertheless, TG and HDL displayed continued elevated levels. Tofacitinib exposure was generally associated with a more remarkable elevation of lipid profiles.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring new avenues: Psychedelic-assisted therapy for young people.","authors":"Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J Nutt, Martina Di Simplicio","doi":"10.1002/bcp.70579","DOIUrl":"https://doi.org/10.1002/bcp.70579","url":null,"abstract":"<p><p>Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic-assisted therapy, using substances such as psilocybin and 3,4-methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including depression, anxiety and post-traumatic stress disorder. Interest has been growing around the potential use of psychedelic-assisted therapy to treat mental illness in adolescents. We present here a comprehensive review of all research focusing on children and young people, from experimental research of the 50s to observational and retrospective research focusing on traditional and Western non-medical use. The limited available research so far suggests that psychedelics appear to be safe overall and may have the potential to improve mental wellbeing in young people. However, young people may be at more risk of experiencing anxiety, challenging experiences and ego dissolution, but more thorough clinical research is warranted. Moving forward, we suggest that psychedelic-assisted therapy for young people should be administered within a rigorous ethical framework, where education of both the young people and their families is incorporated. Family involvement should be considered as part of the therapeutic framework. Lastly, avenues within the psychedelic space should be considered for young people, like the use of lower doses (psycholytic approach), which might lower the potential risks that are seen with high doses.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the human disposition of [¹⁴C]-vebreltinib: Faecal recovery of parent drug and a major circulating metabolite defines its mass balance profile.","authors":"Lijun Li, Weizhe Xue, Hang Yin, Qiannan Gao, Jingxuan Wu, Hepeng Shi, Peilong Zhang, Ruihua Dong","doi":"10.1002/bcp.70605","DOIUrl":"https://doi.org/10.1002/bcp.70605","url":null,"abstract":"<p><strong>Background: </strong>Vebreltinib is a novel, highly selective inhibitor of the hepatocyte growth factor receptor (HGFR, also known as c-MET or MET) tyrosine kinase under development for non-small cell lung cancer. This study aimed to characterize the absorption, metabolism, excretion and mass balance of [¹⁴C]-vebreltinib in humans.</p><p><strong>Methods: </strong>In this open-label study, six healthy Chinese male subjects received a single 200 mg (100 μCi) oral dose of [¹⁴C]-vebreltinib. Serial blood was collected for up to 216-h post-dose. Serial urine and faeces were collected for up to 240-h post-dose. Total radioactivity was measured by liquid scintillation counting, and metabolite profiling was conducted using HPLC-radiochromatography coupled with high-resolution mass spectrometry.</p><p><strong>Results: </strong>Vebreltinib was slowly absorbed, with a mean plasma elimination half-life of 20.1 ± 5.3 h. The half-life of total radioactivity was longer, consistent with the formation and persistence of metabolites. The mean total recovery of radioactivity was 93.0% ± 2.1%, with the majority recovered in faeces (79.5% ± 5.5% of the dose) and 13.5% ± 4.3% recovered in urine. Unchanged vebreltinib was the most abundant drug-related component in excreta, with the N-demethylated metabolite M2 as the major circulating metabolite.</p><p><strong>Conclusion: </strong>Following oral administration, the predominant radioactive component recovered in faeces was unchanged parent drug. The quantitative metabolic profile confirms significant systemic exposure to the M2 metabolite. These data provide critical insights into the human disposition of vebreltinib, including a MIST assessment, and support its continued clinical development.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4⁺ lymphocytes.","authors":"Elizabeth Hastie, Megha Srivasta, Edward R Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z Stanczyk, Craig Sykes, Angela D M Kashuba, Jill Blumenthal, Mackenzie L Cottrell","doi":"10.1002/bcp.70586","DOIUrl":"https://doi.org/10.1002/bcp.70586","url":null,"abstract":"<p><strong>Background: </strong>Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre-exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW). To address this gap, we examined drug metabolites in HIV susceptible cells isolated from blood and rectal tissues of TGW and CGW.</p><p><strong>Materials and methods: </strong>We enrolled 23 TGW, 13 on FHT and 10 CGW. Participants received five directly observed daily PrEP doses: emtricitabine 200 mg with either tenofovir disoproxil fumarate 300 mg (FTC/TDF) or tenofovir alafenamide 25 mg (FTC/TAF). Blood and rectal tissue samples were obtained. Mononuclear and CD4⁺ cells were isolated and analysed for intracellular triphosphorylated nucleotides (TFVdp and FTCtp) and total nucleotide pools (pTFV and pFTC) using HPLC-MS/MS. Serum hormone concentrations were quantified via enzyme immunoassay.</p><p><strong>Results and conclusion: </strong>Total nucleotide pools (pTFV and pFTC) correlated with active metabolites (TFVdp and FTCtp) in blood and rectal CD4⁺ cells (r² > 0.75, p < .001). No significant differences in pTFV or pFTC concentrations were observed between high and low oestradiol groups in either CGW or TGW (p > .1). No correlation was observed between serum oestradiol concentrations and nucleotide concentrations. TAF resulted in 6.8-fold higher median pTFV concentrations in blood CD4⁺ cells (p < .001) but eightfold lower median pTFV concentrations in rectal CD4⁺ cells compared to TDF (p = .008). These findings suggest that neither endogenous hormonal fluctuations in CGW nor exogenous FHT in TGW adversely impact intracellular PrEP pharmacology in key HIV target cells.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomic investigation of cisplatin-induced acute kidney injury in paediatric cancer patients.","authors":"Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T Tsuyuki, S Rod Rassekh, Lesley G Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C Carleton, Geoffrey D E Cuvelier, Victor A Lewis, Colin J D Ross, Alexandra P Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D Blydt-Hansen, Brad L Urquhart","doi":"10.1002/bcp.70587","DOIUrl":"https://doi.org/10.1002/bcp.70587","url":null,"abstract":"<p><strong>Aim: </strong>Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation. Accordingly, there is a need for predictive or early diagnostic biomarkers for cisplatin-induced nephrotoxicity that help determine AKI risk.</p><p><strong>Methods: </strong>Samples from the Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE) study were used. Urine and serum from 86 patients were subjected to an exploratory untargeted metabolomics analysis. Urine and serum samples were collected prior to cisplatin, 24-48 h after cisplatin and 5-14 days after cisplatin. Liquid chromatography-mass spectrometry-based metabolomics was performed on serum and urine to identify predictive or early diagnostic biomarkers of cisplatin-induced AKI.</p><p><strong>Results: </strong>Of the 86 patients included in this study, 34/86 (39.5%) were classified as having AKI based on SCr change from baseline. Overall, there was poor metabolomic discrimination of AKI vs. no-AKI. When patients were stratified by age (≤3 vs. >3 years old), discrimination was greatly improved. Urinary metabolites of the NAD+ synthesis pathway (kynurenine, 2-PY, 1-methlynicotinamide and quinolinate) were found to be significantly elevated in AKI patients compared to no-AKI patients.</p><p><strong>Conclusion: </strong>Urine metabolomic differences exist 24-48 h following cisplatin dosing in paediatric patients who develop AKI. Changes in metabolites involved in the NAD+ synthesis pathway may serve as early indicators of cisplatin-induced nephrotoxicity and may represent promising therapeutic interventions.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":"e70587"},"PeriodicalIF":3.0,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of major congenital malformations based on healthcare databases in France: A proof-of-concept study using the epi-meres nationwide mother-child register.","authors":"Tom Duchemin, Lise Marty, Jérôme Drouin, Sara Miranda, Jérémie Botton, Valérie Olié, Alain Weill, Rosemary Dray-Spira","doi":"10.1002/bcp.70582","DOIUrl":"https://doi.org/10.1002/bcp.70582","url":null,"abstract":"<p><strong>Aim: </strong>Besides registries, healthcare databases can provide useful information for assessing the frequency of major congenital malformations (MCMs) and investigating their risk factors, particularly medication exposures. This study aimed to assess the validity of MCMs identification based on French national, comprehensive healthcare databases.</p><p><strong>Methods: </strong>Using information on hospital discharge diagnoses, medical procedures (e.g. surgery) and death causes from the EPI-MERES register nested in the French National Health Data System, 72 specific MCMs grouped in 11 organ groups were assessed among all births in France between 2010 and 2023. MCMs prevalence rates were estimated and compared to those from EUROCAT, and associations with prenatal exposure to valproate were assessed.</p><p><strong>Results: </strong>Among a total of 10.5 million births, 213 153 live-born infants MCM (203.0 per 10 000 births) with at least one MCM were identified. Almost half (47%) of MCMs cases were identified based on a medical procedure code. MCM prevalence rate increased by 16% between 2010-2012 and 2022-2023, from 181.2 to 211.2 cases per 10 000 births. MCMs prevalence rates among live births were close to those reported in EUROCAT (overall difference: -1%). Prenatal exposure to valproate was significantly associated with increased risks of any MCM (adjusted odds ratio (aOR) 2.82, 95% CI [2.33-3.41]) and of 15 specific MCMs including spina bifida (aOR 17.88 [7.88-40.53]).</p><p><strong>Conclusion: </strong>This study supports the validity of MCMs identification based on data of the EPI-MERES register. The EPI-MERES register provides a highly powerful, reactive and operational tool complementing MCMs registries for improving real-life knowledge on drug teratogenicity.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing the reporting of adverse drug reaction-related hospitalizations using an ICD-10-based identification workflow: A multicentre study from Switzerland.","authors":"Georgia Anita Weber, Sophie-Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E Beeler","doi":"10.1002/bcp.70564","DOIUrl":"https://doi.org/10.1002/bcp.70564","url":null,"abstract":"<p><strong>Background: </strong>Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under-reporting remains widespread. We tested a novel method to increase reporting of ADR-related hospitalizations.</p><p><strong>Methods: </strong>This retrospective observational study used ADR-indicative ICD-10 codes to screen admissions to four Swiss hospitals, identify suspected drugs and send individual case safety reports (ICSRs) of confirmed cases to Swissmedic.</p><p><strong>Results: </strong>Participating hospitals previously reported ~18 ICSRs annually. During the study period (7/2023-12/2023), 200 ADR-related hospitalizations were reported following a review of 814 pre-filtered admissions. Most ICSR data were available in structured format: Median age of patients was 59 (interquartile range [IQR] 42-75); 87 (44%) males; median of two comorbidities (IQR 1-3); the three most frequent ADRs were 'K52.1 Toxic gastroenteritis and colitis' (11 [6%]), 'T42.4 Poisoning by benzodiazepines' (10 [5%]) and 'R11 Nausea and vomiting' (10 [5%]). Discharge reports contained free-text information on suspected drugs: More than half of ADR-related hospitalizations were caused by antineoplastics (45 [23%]), psycholeptics (38 [19%]), opioids and other analgesics (34 [17%]). The median time to screen a case was 1 min, 8 min to collect, compile and send data of confirmed cases.</p><p><strong>Conclusion: </strong>The approach successfully increased reporting of serious ADRs. The time investment for creating ICSRs might soon be rendered obsolete, as most data are available in structured format, and large language models are key to identifying suspected drugs in discharge reports.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":"e70564"},"PeriodicalIF":3.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Comment on revisiting the association between anticholinergic burden and frailty in people with HIV.","authors":"Maria Mazzitelli, Mattia Trunfio, Davide Leoni, Lolita Sasset, Lorenza Barbison, Angela Favaro, Samuele Gardin, Jacopo Farina, Vincenzo Scaglione, Giuseppe Sergi, Annamaria Cattelan","doi":"10.1002/bcp.70597","DOIUrl":"https://doi.org/10.1002/bcp.70597","url":null,"abstract":"","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}